These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36858472)

  • 1. Registry randomised trials: a methodological perspective.
    Doherty DA; Tong SYC; Reilly J; Shrapnel J; McDonald S; Ahern S; Harris I; Tam CS; Brennan AL; Hodgson C; Wilcox L; Balagurunathan A; Butcher BE; Reid CM
    BMJ Open; 2023 Mar; 13(3):e068057. PubMed ID: 36858472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registry-based randomised controlled trials: conduct, advantages and challenges-a systematic review.
    Shiely F; O Shea N; Murphy E; Eustace J
    Trials; 2024 Jun; 25(1):375. PubMed ID: 38863017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining key design elements of registry-based randomised controlled trials: a scoping review.
    Karanatsios B; Prang KH; Verbunt E; Yeung JM; Kelaher M; Gibbs P
    Trials; 2020 Jun; 21(1):552. PubMed ID: 32571382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians.
    Prang KH; Karanatsios B; Zhang A; Verbunt E; Wong HL; Wong V; Gately L; Tran B; Gibbs P; Kelaher M
    Trials; 2023 Feb; 24(1):92. PubMed ID: 36747274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical registries data quality attributes to support registry-based randomised controlled trials: A scoping review.
    Prang KH; Karanatsios B; Verbunt E; Wong HL; Yeung J; Kelaher M; Gibbs P
    Contemp Clin Trials; 2022 Aug; 119():106843. PubMed ID: 35792338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paper II: thematic framework analysis of registry-based randomized controlled trials provided insights for designing trial ready registries.
    Krause KR; Tay J; Douglas WA; Sammy A; Baba A; Goren K; Thombs BD; Howie AH; Oskoui M; Frøbert O; Trakadis Y; Little J; Potter BK; Butcher NJ; Offringa M
    J Clin Epidemiol; 2023 Jul; 159():330-343. PubMed ID: 37146660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registry-based randomized controlled trials merged the strength of randomized controlled trails and observational studies and give rise to more pragmatic trials.
    Mathes T; Buehn S; Prengel P; Pieper D
    J Clin Epidemiol; 2018 Jan; 93():120-127. PubMed ID: 28951111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paper I: Heterogeneous use of registry data for participant identification and primary outcome ascertainment is found in registry-based randomized controlled trials: A scoping review.
    Baba A; Tay J; Sammy A; Douglas WA; Goren K; Krause KR; Howie AH; Little J; Oskoui M; Taljaard M; Thombs BD; Potter BK; Butcher NJ; Offringa M
    J Clin Epidemiol; 2023 Jul; 159():289-299. PubMed ID: 37146658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No differences were found between effect estimates from conventional and registry-based randomized controlled trials.
    Mathes T; Klaßen P; Pieper D
    J Clin Epidemiol; 2019 Jan; 105():80-91. PubMed ID: 30257186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities and barriers for the use of Australian cancer registries as platforms for randomized clinical trials.
    Yan MK; Adler NR; Heriot N; Shang C; Zalcberg JR; Evans S; Wolfe R; Mar VJ
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):344-352. PubMed ID: 34811922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions.
    Lund LH; Oldgren J; James S
    Curr Heart Fail Rep; 2017 Apr; 14(2):59-70. PubMed ID: 28247180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?
    Li G; Sajobi TT; Menon BK; Korngut L; Lowerison M; James M; Wilton SB; Williamson T; Gill S; Drogos LL; Smith EE; Vohra S; Hill MD; Thabane L;
    J Clin Epidemiol; 2016 Dec; 80():16-24. PubMed ID: 27555082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?
    Eriksson JW; Eliasson B; Bennet L; Sundström J
    Diabetologia; 2022 Oct; 65(10):1575-1586. PubMed ID: 35902386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data.
    Fitzpatrick T; Perrier L; Tricco AC; Straus SE; Jüni P; Zwarenstein M; Lix LM; Smith M; Rosella LC; Henry DA
    BMJ Open; 2017 Feb; 7(2):e013770. PubMed ID: 28213601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme.
    Raftery J; Young A; Stanton L; Milne R; Cook A; Turner D; Davidson P
    Health Technol Assess; 2015 Feb; 19(11):1-138. PubMed ID: 25671821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimum number of clusters and comparison of analysis methods for cross sectional stepped wedge cluster randomised trials with binary outcomes: A simulation study.
    Barker D; D'Este C; Campbell MJ; McElduff P
    Trials; 2017 Mar; 18(1):119. PubMed ID: 28279222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Logistic, ethical, and political dimensions of stepped wedge trials: critical review and case studies.
    Prost A; Binik A; Abubakar I; Roy A; De Allegri M; Mouchoux C; Dreischulte T; Ayles H; Lewis JJ; Osrin D
    Trials; 2015 Aug; 16():351. PubMed ID: 26278521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of varying cluster size in cross-sectional stepped-wedge cluster randomised trials.
    Martin JT; Hemming K; Girling A
    BMC Med Res Methodol; 2019 Jun; 19(1):123. PubMed ID: 31200640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.